Globus Medical, Inc.
GMEDHealthcareNASDAQMedical Devices · Last scanned Jun 2, 2026
Scan Results
Daily timeframeGlobus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. With a market capitalization of $10.83B, it sits in large-cap territory. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.
Market Cap
$10.83B
Beta
1.00
P/E (TTM)
18.64
P/E (Fwd)
15.49
EPS (TTM)
$4.28
EPS (Fwd)
$5.15
ROE
13.3%
ROA
8.2%
Cash
$629.9M
Total Debt
$115.9M
Free CF
$341.1M
52W Change
33.6%
Annual Financials
Cash vs Debt
Globus Medical, Inc. holds $629.9M in cash against $115.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $341.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 13.3% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $2.94B (2025), reflecting a 187% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Globus Medical, Inc.'s trajectory.